Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829373 · ClinicalTrials.gov registry record · Phase 1
Lung Cancer Vaccine Plus Oral Dietary Supplement
A Phase 1 study, sponsored by Edward Hirschowitz.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01829373: Completed Phase 1 study, sponsored by Edward Hirschowitz.
NCT01829373 is a Phase 1 study that has completed, run by Edward Hirschowitz. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01829373, a Phase 1 study, has completed, sponsored by Edward Hirschowitz.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study tests the ability of the allogeneic cellular vaccine 1650-G vaccine to enhance immune recognition of tumor cells in patients with lung cancer. The vaccine is combined with an oral medication called beta glucan, an over the counter oral dietary supplement that may also stimulate the immune system in ways that helps the body eradicate cancer cells and reduce risk of recurrent cancer. The primary purpose of this study is to measure the changes in the number of immune cells that might help lower risk of cancer recurrence. The investigators do not yet know if the vaccine is effective in fighting cancer and will not know at the end of this study whether this has been of benefit.
Primary Outcome
Increase in number of peripheral blood T cells recognizing cancer antigens
Interventions
- BIOLOGICAL vaccine 1650-G
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
What the finished NCT01829373 record still lists
NCT01829373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which vaccine 1650-G is the first listed.
NCT01829373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01829373 about?
NCT01829373 is a clinical study titled "Lung Cancer Vaccine Plus Oral Dietary Supplement". This study tests the ability of the allogeneic cellular vaccine 1650-G vaccine to enhance immune recognition of tumor cells in patients with lung cancer. The vaccine is combined with an oral medication called beta glucan, an over the counter oral dietary supplement that may also stimulate the immune...
What is the current status of trial NCT01829373?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2011-10. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01829373?
The interventions under investigation include: vaccine 1650-G (BIOLOGICAL).
Who is sponsoring clinical trial NCT01829373?
This trial is sponsored by Edward Hirschowitz, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01829373's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia